An interventional study of Eye Movement Desensitization and Reprocessing (EMDR) for psychosis in Psychiatric Diagnosis, Schizophrenia Disorders and Psychological Trauma, Historical, sponsored by Haukeland University Hospital. Recruiting at 11 sites in Norway. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Haukeland University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Schizophrenia spectrum disorders (SSDs) have a significant trauma etiology: trauma has been reported in 65 - 80% in this patient group and have a negative impact on prognosis. Trauma treatment is currently not offered in SSDs due to a lack of evidence. KIT is a pragmatic trial comparing the effectiveness of added trauma focused therapy, Eye Movement Desensitization and Reprocessing (EMDR) to standard treatment in SSDs.
The study will compare EMDR as add on to treatment as usual (TAU) to TAU in patients with schizophrenia spectrum disorders (SSDs). The overall aim is to examine the effectiveness of EMDR on trauma symptoms in SSDs.
Participants will receive max. 26 sessions of EMDR, and complete assessments before, during and after the course of therapy, in addition to a period of time (6 months) after therapy to examine long-term effects.
The KIT trial is a pragmatic, assessor-blinded, parallel 2-group, superiority randomized trial comparing the addition of EMDR to treatment as usual (TAU) versus waiting list (WL) and TAU for EMDR on symptoms of trauma in patients with SSDs. Participants will be randomized (1:1, block randomization by center and gender) to one of the two groups.
Aims, hypotheses, objectives:
Expected results during the project period:
EMDR for psychosis therapists: Eighteen trial therapists are currently fully trained in EMDR for psychosis in collaboration with Dr. Varese and colleagues at Manchester University, and receive monthly supervision. At least 24 more will be trained by early 2025. Assuming some therapist drop-out, 40 trial therapists will be recruiting SSD patients from their patient lists.
Assessments: Assessments will be performed for both groups by blinded research personnel at baseline, mid-treatment (12 weeks), end of treatment (6 months), 6- and 12-months post randomisation after end of treatment, in addition to digital patient feedback every 2 weeks from baseline to end of treatment at 6 months. The follow-up period after end of treatment is to examine long-term effects.
Eligible participants will be given initial information (verbal, web page, pamphlets) by the trial therapists, and then verbal and written information by research staff and asked for informed consent to partake in the trial. Primary outcome will be measured by the ITQ, a validated measure assessing reliable and clinically significant treatment-related change in trauma symptoms, including symptoms of PTSD and complex PTSD, used in outpatient clinics in Norway. Demographic and clinical information will be supplemented by clinical records and national health registers (e.g. Legemiddel-registeret, Kontroll og utbetaling av helserefusjoner, Kommunalt pasient og bruker-register, Norsk pasientregister, Nasjonalt kvalitetsregister for behandling i psykisk for voksne). Healthcare costs (e.g. use of all health care, health related financial support, transportation) will be captured by the study nurses at each assessment point and through health registers.
Patients' experience of trauma symptoms, working alliance and recovery will be assessed through Norse Feedback digital self-report. The digital assessment of the main outcome trauma symptoms (ITQ) will be captured every 2 weeks to closely monitor symptom fluctuations, while recovery and therapist alliance follow the time points of the study nurse assessments. This decentralised assessment is deemed particularly suitable in mental health. Assessment of somatic status (heartrate, weight, blood pressure) will be supplemented by blood samples of inflammation markers (CRP, IL6 and S-cortisol) and blood samples to the Bergen Psychosis Biobank for later analysis (e.g. IL18). The digital biomarkers heart rate variability, respiration rate (electro- cardiography/photoplethysmography), activation/ movement (actigraphy) and skin conductance (electrodermal activity) will be measured in-session by BioPoint wristworn biosensor. Trial therapists will rate fidelity, patient safety related adverse events (AE) and symptom exacerbation after each session, and variables facilitating implementation before/after trial participation. For symptom-specific items on suicidality, psychosis, substance abuse and hospitalisations. A sub-group of 30 patients will be asked about their experience of the therapy with a qualitative interview after treatment.
Work packages: Quality of assessments and analysis will be ensured by organising themes in work packages (WP) headed by national experts; WP0 Study management, WP1 Clinical outcome, WP2 Somatic status and biomarkers, WP3 Trauma characteristics, WP4 Treatment alliance and user experience, WP5 Study imple-mentation, WP6 Health economic evaluation.
Protocol adherence: Hospital Clinical Monitor will ensure protocol implementation and site responsibility. The protocol will be adhered to by all trial personnel, including trial therapists and local PIs to ensure patient safety and trial quality. There will be frequent meetings across sites and written agreements on site responsibility. All sites will use electronic report files (CRF) via Viedoc for patient case report forms.
Organization: The KIT trial is organized in Bergen Psychosis Research Group (BPRG) at Haukeland University Hospital. BPRG has extensive experience from clinical trials on SSDs (ClinicalTrials.gov IDs NCT00932529, NCT01446328, NCT03340909, NCT02597439, NCT02146547).
1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.
This study's planned enrollment of 187 is above the median of 100 across 1,305 interventional studies indexed under Mental Disorders.
Browse Mental Disorders studies →Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 58 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
acute state of psychosis defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to receive max. 26 sessions of EMDR for psychosis.
Other: Eye Movement Desensitization and Reprocessing (EMDR) for psychosis
Patients randomized to continue with treatment as usual (TAU) for 6 months as a waiting list (WL) control group. TAU consists of an individual combination of treatments for SSDs in line with Norwegian national guideline (e.g. medication, cognitive therapy, work training, music therapy).
EMDR aims to treat and process trauma by safely retrieving the trauma memories while taxing the working memory. EMDR targets trauma symptoms through memory reprocessing of traumatic memories, and consists of eight flexible phases: history taking/case conceptualization; preparation for memory reprocessing; assessment/identification of a target memory; desensitization/reprocessing; installation of positive cognition; body scan; closure; and re-evaluation. EMDR in the current trial has psychosis-specific adaptations including focus on psychoeducation, preparation for reprocessing and patient safety. Techniques targeting dissociation, psychotic symptoms and psychosis-related challenges are included.
Trauma symptoms
Primary outcome is trauma symptoms as measured by the International Trauma Questionnaire. PTSD symptom scale range from 0 to 24. Higher scores indicate more sever trauma symptoms.
Time frame: From baseline to end of treatment at 6 months.
Severity of psychosis symptoms
Secondary outcome is psychosis symptoms as measured by the The Positive and Negative Syndrome Scale (PANSS), which ranges from 30 to 210, with higher scores indicating more severity.
Time frame: From baseline to end of treatment at 6 months.
The rate of autonomic arousal during trauma processing
Digital biomarkers measured with BioPoint wrist-worn device. Physiological stress reactivity is recorded non-invasively and continuously, offering an especially suitable means for monitoring objective physiological responses. Real-time assessments of hyperarousal, autonomic and somatic reactivity, and stress reactivity (including heart rate variability, skin conductance, respiration, and actigraphy) will be administered during EMDR sessions.
Time frame: Baseline to end of treatment at 6 months.
Inflammation
Measure of inflammation markers (CRP, IL6) using blood samples
Time frame: Baseline and end of treatment at 6 months
Clinical stratification by trauma type and severity measured by the Childhood Trauma Questionnaire
Trauma type and severity as measured by the Childhood Trauma Questionnaire short form (CTQ-SF). CTQ-SF ranges from 25 to 125, with higher scores indicating more severe childhood trauma. Subscale scores range from 5-25 for the following sub scales: physical, emotional and sexual abuse, and physical and emotional neglect.
Time frame: Baseline to end of treatment at 6 months.
Adverse events
No differences in adverse events is expected between the groups.
Time frame: Baseline to end of treatment at 6 months.
Health care costs
No difference in health care costs is expected between the groups.
Time frame: Baseline to end of treatment at 6 months.
Clinical stratification by trauma type and severity measured by the Traumatic experiences checklist
Severity and type of trauma measured by the Traumatic Experiences Checklist (TEC). The TEC indicates the presence of trauma on a scale from 0-29, higher scores indicating more exposure. TEC also include composite scores from 0-12 by developmental period, where higher scores indicate more severity.
Time frame: Baseline to end of treatment at 6 months.
Clinical stratification by trauma symptoms measured by the International Trauma Questionnaire
Trauma symptoms measured by the International Trauma Questionnaire (ITQ). The ITQ ranges from 0-24 for PTSD symptoms and 0-24 for symptoms of complex PTSD, where higher scores indicate more severe symptoms. There is also a diagnostic algorithm for PTSD and complex PTSD status.
Time frame: Baseline to end of treatment at 6 months.
Plan to share: No — This is not feasible due to Norwegian policies in clinical research.
Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.
Of 668 non-industry interventional studies with no phase under Mental Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 45. This study's planned 39 months is above that.
Counting every sponsor, half of 682 studies reached it within 29 months; a quarter within 13 and three quarters within 45.
Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haukeland University Hospital →